Stomach cancer laboratory findings
|
Stomach cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Stomach cancer laboratory findings On the Web |
|
American Roentgen Ray Society Images of Stomach cancer laboratory findings |
|
Risk calculators and risk factors for Stomach cancer laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
0verview
Stomach cancer laboratory findings
- A complete blood cell count (CBC) can identify anemia
- Liver function tests may be disturbed in many patients with liver metastasis
- Carcinoembryonic antigen (CEA) is elevated in 50% of patients
- Cancer antigen (CA) 19-9 is elevated
- Distinctive serum glycan patterns may have the potential to serve as markers for gastric cancer risk. In a study of 72 serum samples from patients with gastric cancer, nonatrophic gastritis, or duodenal ulcer, Ozcan and colleagues found that abnormal patterns of serum glycans (sugars attached to proteins) may be useful as a screening tool for identifying patients with Helicobacter pylori infection who are at risk for stomach cancer. [[null 30], [null 31]]
- Glycoprotein CA 125 antigen
- Carbohydrate antigen 19-9 (CA 19-9)
- Cancer antigen 72-4 (CA72-4) may be elevated [68-72].
- Alpha-fetoprotein (AFP) may be elevated [85-88]
- A drop in an elevated level of CEA means response to preoperative therapy. Due to , low rates of sensitivity and specificity, serologic markers can not be used as diagnostic tests for gastric cancer.